{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+hydrochloride&page=5", "query": { "intervention": "Mitoxantrone hydrochloride", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 176, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+hydrochloride&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+hydrochloride&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T09:07:43.754Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02583893", "title": "Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2015-10-07", "completion_date": "2023-05-17", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-12T09:07:43.754Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02583893" }, { "nct_id": "NCT01342887", "title": "Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "cyclosporine", "type": "DRUG" }, { "name": "pravastatin sodium", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "bone marrow aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2011-04", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-12T09:07:43.754Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01342887" }, { "nct_id": "NCT01184898", "title": "Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "AML" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2010-07", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-10-12T09:07:43.754Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01184898" }, { "nct_id": "NCT02484391", "title": "CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Granulocytic Sarcoma", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "6,8-Bis(benzylthio)octanoic Acid", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2015-09", "completion_date": "2022-02-02", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-12T09:07:43.754Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02484391" }, { "nct_id": "NCT00015951", "title": "Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2001-04", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-10-12T09:07:43.754Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Baltimore, Maryland", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00015951" }, { "nct_id": "NCT02039726", "title": "(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "AML" ], "interventions": [ { "name": "Quizartinib", "type": "DRUG" }, { "name": "Salvage Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2014-05", "completion_date": "2020-09-08", "has_results": true, "last_update_posted_date": "2021-02-24", "last_synced_at": "2026-10-12T09:07:43.754Z", "location_count": 36, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 31 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02039726" }, { "nct_id": "NCT03250338", "title": "Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations" ], "interventions": [ { "name": "Crenolanib", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arog Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 106, "start_date": "2018-08-16", "completion_date": "2026-04-03", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-12T09:07:43.754Z", "location_count": 9, "location_summary": "Sacramento, California • Gainesville, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03250338" }, { "nct_id": "NCT00477087", "title": "Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "18 Years to 75 Years · Male only" }, "enrollment_count": 10, "start_date": "2006-07", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-10-12T09:07:43.754Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477087" }, { "nct_id": "NCT00562965", "title": "Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Follicular" ], "interventions": [ { "name": "inotuzumab ozogamicin", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone/prednisolone", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-11", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-10-12T09:07:43.754Z", "location_count": 17, "location_summary": "Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more", "locations": [ { "city": "Mission Hills", "state": "California" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Novi", "state": "Michigan" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00562965" }, { "nct_id": "NCT00004124", "title": "S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "bicalutamide", "type": "DRUG" }, { "name": "goserelin", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": 983, "start_date": "1999-10-15", "completion_date": "2018-05-01", "has_results": true, "last_update_posted_date": "2022-12-30", "last_synced_at": "2026-10-12T09:07:43.754Z", "location_count": 234, "location_summary": "Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 157 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004124" } ] }